Arcadia Biosciences and Ardent Mills Announce Collaboration to Develop and Commercialize Wheat Innovations
— Initial project focuses on extending shelf life of whole wheat and promoting whole grain consumption —
DENVER, Colo. and DAVIS, Calif. (November 6, 2018) – Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, and Ardent Mills, LLC, North America’s leading flour-milling and ingredient company, today announced a collaboration to develop and commercialize innovative wheat varieties. The first project focuses on extending the shelf life and improving the flavor of whole wheat products.
“For several years, we have been investing in this strategy. We see this trait as a big and important step forward that will benefit bakers, food manufacturers, the food service industry, and ultimately consumers,” stated Ardent Mills CEO Dan Dye.
Using patented Arcadia trait technology, the storage life of whole wheat flour can be extended by slowing the enzymatic processes that reduce shelf life. Because milled flour from wheat carrying Arcadia’s trait technology oxidizes more slowly, it also minimizes the bitterness associated with most whole wheat products. This trait is expected to help improve the taste of whole wheat products and help reduce waste.
The Extended Shelf Life wheat trait was developed using Arcadia’s proprietary non-GM wheat genetic diversity library, an extensive and exclusive resource of trait lines with high-density variations in genetic composition and gene function. Because it is non-GM, the trait has wide application potential across both conventional and organic farming practices. The company recently received a U.S. patent for the technology, the latest in Arcadia’s portfolio of wheat trait improvements.
“This new trait was developed through traditional breeding. While innovative thinking has brought it this far, further collaboration will continue between Ardent Mills, Arcadia and university partners to bring this trait to commercial reality,” said Shrene White, General Manager, The Annex by Ardent Mills.
“As the leading flour supplier and grain innovator in North America, Ardent Mills is the ideal partner to bring this technology to the market,” said Raj Ketkar, president and CEO of Arcadia. “Wheat is an important source of fiber, protein, nutrients and minerals for consumers throughout the world, and these creative approaches to improving the functional properties of wheat can have a significant impact on the future of whole grain consumption.”
About Ardent Mills, LLC Ardent Mills is the premier flour-milling and ingredient company whose vision is to be the trusted partner in nurturing its customers, consumers and communities through innovative and nutritious grain-based solutions. Ardent Mills’ operations and services are supported by more than 40 flour mills and bakery-mix facilities along with a specialty bakery, Ardent Mills Innovation Center and Mobile Innovation Center, all located in the U.S., Canada and Puerto Rico. Deeply rooted in communities throughout North America, Ardent Mills is headquartered in Denver, Colorado and employs more than 100 certified millers, supporting thousands of local jobs and contributing billions of dollars to local economies. To learn more about Ardent Mills, visit ardentmills.com.
About Arcadia Biosciences, Inc. Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company’s agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ and affiliates’ ability to develop commercial products incorporating their traits, and complete the regulatory review process for such products; Arcadia’s compliance with laws and regulations that impact Arcadia’s business, and changes to such laws and regulations; Arcadia’s future capital requirements and ability to satisfy its capital needs; Arcadia’s ability to develop, enforce and defend its intellectual property rights; and the other risks set forth in Arcadia’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2017 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Mary Ann Strombitski